[01] Proma Chakraborty, Department of Biotechnology, Reva University, Rukmini Knowledge Park, Yelahanka, Bangalore, India; Department of Life Sciences, Garden City College of Science and Management Studies, Bangalore, India. [02] Mani Ramakrishnan, Department of Biotechnology, Reva University, Rukmini Knowledge Park, Yelahanka, Bangalore, India; PG Department of Bioscience, CMR Institute of Management Studies, OMBR Layout, Banaswadi, Bangalore, India.

P-glycoprotein (P-gp) is considered to be the multi-drug resistance integral membrane bound protein with a size of 170kDa, responsible for energy dependent efflux transport through ATP hydrolysis. In the normal and even in cancer cells, physiologically the pump prevents the destructive presence of poisons, drugs and xenobiotics to the body by expelling them out and maintaining the blood brain barrier. P-gp is found to play the fundamental regulator role in the pharmacokinetic properties of numerous clinically imperative therapeutic agents. The designing of cancer chemotherapy has turned out to be progressively modern, yet there is no malignancy treatment that is 100% successful against dispersed growth. Resistance to treatment with anticancer drugs results from a variety of factors which mainly includes polymorphic variations and genetic differences in tumours. The most well known explanation behind obtaining resistance to a broad range of anticancer drugs is influenced by the expression of one or more energy-dependent transporters (P-gp pumps or multi drug transporter) that detect and eject anticancer drugs from cells. A number of potential chemicals commonly known as inhibitors has been identified that can deactivate P-gp but has adverse effect on the host.

P-glycoprotein, Multidrug Resistance (MDR), Drug Transporters, P-glycoprotein Inhibitors

[01] Berg J M, Tymoczko J L, Stryer L; Biochemistry; Chapter 13 Membrane Channels and Pumps; 5 ^th edition; New York: W H Freeman; p 528-568 (2002). [02] Linn J H, Yamazaki M; Role of P-glycoprotein in pharmacokinetics clinical implications. Clin Pharmacol 42: p 59–98 (2003). [03] Sharom F J; The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol. 1; 160 (3): p 161-75 Dec (1997). [04] Dean M, Rzhetsky A, Allikmets R; The human ATP-binding cassette (ABC) transporter superfamily. Genome Res; 11: p 1156–66 (2001). [05] Venter J C, Adams M. D, Myers E W, Li P W, Mural R J, Sutton G G, et. al; The sequence of the human genome. Science; 291: p 1304–51 (2001). [06] Gottesman M N, Pastan I; Biochemistry of multidrug resistance mediated by multi drug transporter. Annu Rev Biochem: 62: p 385–427 (1993). [07] Loo T W, Clarke D M; Identification of the distance between the homologous halves of P-glycoprotein that triggers the high/low ATPase activity switch; J Biol Chem; 289 (12): p 8484-92 (2014). [08] Hrycyna C A, Airan L E, Germann U A, Ambudkar S V, Pastan I, Gottesman M M; Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry; 37: p 13660–73 (1998). [09] Hung L W, Wang I, Nikaido K; Crystal Structure of the ATP-binding subunits of an ABC transporter. Nature; 396: p 703–7 (1998). [10] Booth C L, Pulaski L, Gottesman M M, Pastan I; Analysis of the properties of the N-terminal nucleotide-binding domain of human P-glycoprotein. Biochemistry; 39: p 5518–26 (2000). [11] Tombline G, Bartholomew L, Gimi K, Tyndall G A, Senior A E; Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis. J Biol Chem; 279: p 5363–73 (2004). [12] Yasuhisa K, Michinori M, Kei T, Tohru S, Noriyuki K; ATP hydrolysis dependent multidrug efflux transporter: MDR1/P-glycoprotein. Current Drug Metabolism; 5: p 1–10 (2004). [13] Ambudkar S V, Dey S, Hrycyna; Biochemical, cellular and pharmacological aspects of multidrug transporter. Annu Rev Pharmacol Toxicol; 39: p 361–98 (1999). [14] Ueda K, Taguchi Y, Morishima M; How does P-glycoprotein recognize its substrates. Semin Cancer Biol; 8: p 151–9 (1997). [15] Tip W, Loo M, Claire B, David M C; Val 133 and Cys 137 in Transmembrane Segment 2 Are Close to Arg 935 and Gly 939 in Transmembrane Segment 11 of Human P-glycoprotein. J Biol Chem; 279: p 18232–38 (2005). [16] Mark F R, Richard C, Szabolcs M, Christopher F H, Robert C F; Three dimensional Structure of P-glycoprotein The transmembrane regions adopt anasymmetric configuration in the nucleotide-bound state. J Biol Chem; 280: p 2857–62 (2005). [17] Shimabuku A M, Nishimoto T, Ueda K, Komano T; P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem; 267: p 4308–11 (1992). [18] Hrycyna C A, Ramachandra M, Ambudkar S V, Ko Y H, Pedersen P L, Pastan I, et. al; Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem; 273: p 16631–4 (1998). [19] Ambudkar S V, Dey S, Hrycyna C A; Biochemical, cellular and pharmacological aspects of multidrug transporter. Annu Rev Pharmacol Taxicol; 39: p 361–98 (1999). [20] Shapiro A B, Ling V; Stoichiometry of coupling of rhodamine 123 transporter to hydrolysis by human P-glycoprotein. Eur J Biochem; 254: p 189–93 (1998). [21] Sauna Z E, Ambudkar S V; Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Nat l Acad Sci; 97: p 2515–20 (2000). [22] Sauna Z E, Smith M M, Muller M, Kerr K M, Ambudkar S V; The mechanism of action of multidrug-resistance – linked P-glycoprotein. J Bioenerg Biomembr; 33: p 481–91 (2001). [23] Takada Y, Yamada T Y; Non equivalent cooperation between the two nucleotide binding folds of P-glycoprotein. Biochim Biophys Acta; 1373: p 131–6 (1998). [24] Urbatsch I L, Tyndall G A, Tombline G, Senior A E; P-glycoprotein catalytic mechanism studies of the ADP-vanadate inhibited state. J Biol Chem; 278: p 23171–9 (2003). [25] Hou Y X, Cui L, Riordan J R, Chang X B; ATP binding to the first nucleotide binding domain of multidrug resistance protein MRP1 increases binding and hydrolysis of ATP and trapping of ADP at the second domain. J Biol Chem; 277: p 5110–9 (2002). [26] Loo T W, Clarke D M; The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface; J Biol Chem; 274 (35): p 24759-65 (1999). [27] Mark F R, Alhaji B K, Richard C, Christopher F H, Robert C F; Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem; 278: p 8294–99 (2003). [28] Vishal R. Tandon, B. Kapoor, G. Bano, S. Gupta, Z. Gillani, S. Gupta, D. Kour; P-Glycoprotein: pharmacological relevance; Indian J Pharmacol; Vol 38; Issue 1; p 13-24: February (2006). [29] Loo T W, Clarke D M; Do drug substrates enter the common drug-binding pocket of P-glycoprotein through “gates”? Biochem Biophys Res Commun; 329: p 419–22 (2005). [30] Md. Lutful Amin; P-glycoprotein Inhibition for Optimal Drug Delivery; Drug Target Insights: 7; p 27–34 (2013). [31] Genevieve Housman, Shannon Byler, Sarah Heerboth, Karolina Lapinska, Mckenna Longacre, Nicole Snyder and Sibaji Sarkar. Drug Resistance in Cancer: An Overview, Cancers, 6, p 1769-1792; doi: 10.3390/cancers6031769; (2014). [32] Loo T W, Clarke D M; The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface; J Biol Chem; 274 (35): p 24759-65 (1999). [33] Choudhuri S K; Deactivation of P-glycoprotein by a novel compound, oxalyl-bis (N-phenyl) hydroxamic acid. Neoplasma, p 272-7, (2002). [34] Lampidis T J, Kolonias D, Podona T, Israel M, Safa A R, Lothstein L, Savaraj N, Tapiero H & Priebe W; Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry, 36, p 2679-2685 (1997). [35] Toru Watanabe, Noriko Kokubu, Steven B, Charnick, Mikihiko Naito, Takashi Tsuruo & Dalia Cohen; Interaction of cyclosporine derivatives with the ATPase activity of human P-glycoprotein; British Journal of Pharmacology, 122, p 241–248 (1997). [36] Kale Mohana, Raghava Srivalli, P. K. Lakshmi; Overview of P-glycoprotein inhibitors: a rational outlook; Brazilian Journal of Pharmaceutical Sciences vol. 48, n. 3, p 353-367, July/Sep (2012). [37] Dantzig A H, De Alwis, D P, Burgess M; Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev, v. 55, p. 133-150 (2003). [38] Darby R A, Callaghan R; McMahon R M; P-Glycoprotein inhibition; the past, the present and the future. Curr. Drug Metab, v. 12, p 722-731 (2011). [39] Thomas H, Coley H M; Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control, v. 10, p 159-165 (2003). [40] Pick A, Muller H, Mayer R, Haenisch B, Pajeva I K, Weigt M, et. al; Structure–activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP), Bioorganic & Medicinal Chemistry, Volume 19, Issue 6, p 2090–2102, 15 March (2011). [41] Hossam M. Abdallah, Ahmed M. Al-Abd, Riham Salah El-Dine, Ali M. El-Halawany; P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review; Journal of Advanced Research, Volume 6, Issue 1, p 45–62, January (2015). [42] Jana Broecker, Sebastian Fiedler, Sandro Keller; Complete and Reversible Chemical Unfolding of an α-Helical Membrane Protein; Biophysical Journal, Volume 104, Issue 2, Supplement 1, p62a, 29 January (2013). [43] Floriane Montanari, Barbara Zdrazil, Daniela Diglesand Gerhard F. Ecker; Selectivity profiling of BCRP versus P‑gp inhibition: from automated collection of polypharmacology data to multi‑label learning; Journal of Cheminformatics 8: 7; February (2016). [44] Veda Prachayasittikul, Virapong Prachayasittikul; P-Glycoprotein transporter in drug development; EXCLI Journal; 15–ISSN 1611-2156: p 113-118; February (2016).